Mendelian Randomization Study on the Correlation between Genetic Prediction Frailty Index and Stroke

Abstract

Abstract: Objective To analyze the correlation between genetic prediction of frailty index (FI) and stroke using Mendelian randomization method (MR). Methods Instrumental variables (IVs) associated with flimsy index (FI) were obtained from a large genome-wide association study (GWAS). Inverse variance weighting was used to estimate the causal effect, and multi-factor MR Analysis was used to eliminate the effects of body mass index (BMI), inflammatory bowel disease, and C-reactive protein on outcomes to evaluate the independent causal effect of FI and stroke. Results MR Results showed an association between genetically predicted FI and a higher risk of any stroke(OR = 1.360, 95%CI: 1.006-1.838, P = 0.046). For stroke subtypes, gene-predicted FI was associated with a higher risk of large atherosclerotic stroke(LAS, OR = 2.482, 95%CI: 1.279-4.816, P = 0.007). There was no causal relationship between genetically predicted FI and ischemic stroke, intracranial hemorrhage, cardiac embolic stroke, and small artery stroke. Multivariate MR Analysis showed that after adjusting for IBD, the association between genetically predicted FI and large atherosclerotic stroke(LAS) was weakened(P = 0.114). Conclusion MR Studies show that gene predicted FI is closely related to stroke. Subgroup analysis showed that gene predicted FI was correlated with LAS, but not with IS, CES, SAS, and ICH.

Key words: frailty, stroke, Mendelian randomization, atherosclerosis, large atherosclerotic stroke

CLC Number:

R743.3

LIU Jia, LIU Hong-min, GUI Yuan-yuan, YIN Lei, JIA Jing-jing. Mendelian Randomization Study on the Correlation between Genetic Prediction Frailty Index and Stroke[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(11): 4-9.

References

[1] CLEGG A, YOUNG J, ILIFFE S, et al.Frailty in elderly people[J]. Lancet(London, England),2013,381(9868):752-762.
[2] CHEN X, MAO G, LENG S X.Frailty syndrome: an overview[J]. Clin Interv Aging,2014,9:433-441.
[3] EVANS N R, TODD O M, MINHAS J S, et al.Frailty and cerebrovascular disease: Concepts and clinical implications for stroke medicine[J]. Int J Stroke,2022,17(3):251-259.
[4] KILKENNY M F, PHAN H T, LINDLEY R I, et al.Utility of the Hospital Frailty Risk Score Derived From Administrative Data and the Association With Stroke Outcomes[J]. Stroke,2021,52(9):2874-2881.
[5] PALMER K, VETRANO D L, PADUA L, et al.Frailty Syndromes in Persons With Cerebrovascular Disease: A Systematic Review and Meta-Analysis[J]. Front Neurol,2019,10:1255-1262.
[6] LAWLOR D A, HARBORD R M, STERNE J A C, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology[J]. Stat Med,2008,27(8):1133-1163.
[7] ATKINS J L, JYLHÄVÄ J, PEDERSEN N L, et al. A genome-wide association study of the frailty index highlights brain pathways in ageing[J]. Aging Cell,2021,20(9):e13459.
[8] DAVEY SMITH G, HOLMES M V, DAVIES N M, et al.Mendel’s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues[J]. Eur J Epidemiol,2020,35(2):99-111.
[9] SWERDLOW D I, KUCHENBAECKER K B, SHAH S, et al.Selecting instruments for Mendelian randomization in the wake of genome-wide association studies[J]. Int J Epidemiol,2016,45(5):1600-1616.
[10] DAVEY SMITH G, HEMANI G.Mendelian randomization: genetic anchors for causal inference in epidemiological studies[J]. Hum Mol Genet,2014,23(R1):R89-98.
[11] HEMANI G, ZHENG J, ELSWORTH B, et al.The MR-Base platform supports systematic causal inference across the human phenome[J]. eLife,2018,7:e34408.
[12] CHEN L, YANG H, LI H, et al.Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study[J]. Hepatology,2022,75(4):785-796.
[13] SANDERSON E, SPILLER W, BOWDEN J.Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization[J]. Stat Med,2021,40(25):5434-5452.
[14] MALIK R, CHAUHAN G, TRAYLOR M, et al.Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes[J]. Nat Genet,2018,50(4):524-537.
[15] BURGESS S, BUTTERWORTH A, THOMPSON S G.Mendelian randomization analysis with multiple genetic variants using summarized data[J]. Genet Epidemiol,2013,37(7):658-665.
[16] BURGESS S, THOMPSON S G.Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects[J]. Am J Epidemiol,2015,181(4):251-260.
[17] BURGESS S, BOWDEN J, FALL T, et al.Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants[J]. Epidemiology,2017,28(1):30-42.
[18] BOWDEN J, DEL GRECO M F, MINELLI C, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization[J]. Stat Med,2017,36(11):1783-1802.
[19] BOWDEN J, DAVEY SMITH G, BURGESS S.Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J]. Int J Epidemiol,2015,44(2):512-525.
[20] BOWDEN J, SPILLER W, DEL GRECO M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression[J]. Int J Epidemiol,2018,47(4):1264-1278.
[21] HEMANI G, BOWDEN J, DAVEY SMITH G.Evaluating the potential role of pleiotropy in Mendelian randomization studies[J]. Hum Mol Genet,2018,27(R2):R195-R208.
[22] BURGESS S, THOMPSON S G.Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol,2017,32(5):377-389.
[23] LOCKE A E, KAHALI B, BERNDT S I, et al.Genetic studies of body mass index yield new insights for obesity biology[J]. Nature,2015,518(7538):197-206.
[24] DÖNERTAŞ H M, FABIAN D K, VALENZUELA M F, et al. Common genetic associations between age-related diseases[J]. Nat Aging, 2021,1(4):400-412.
[25] LIGTHART S, VAEZ A, VÕSA U, et al. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders[J]. Am J Hum Genet,2018,103(5):691-706.
[26] OFORI-ASENSO R, CHIN K L, MAZIDI M, et al.Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis[J]. JAMA netw open,2019,2(8):e198398.
[27] MITNITSKI A B, MOGILNER A J, ROCKWOOD K.Accumulation of deficits as a proxy measure of aging[J]. The Scientific World Journal,2001,1:323-336.
[28] HOOGENDIJK E O, AFILALO J, ENSRUD K E, et al.Frailty: implications for clinical practice and public health[J]. Lancet,2019,394(10206):1365-1375.
[29] DENT E, KOWAL P, HOOGENDIJK E O.Frailty measurement in research and clinical practice: A review[J]. Eur J Intern Med,2016,31:3-10.
[30] DOU M, CEN Y, ZHONG J, et al.Association between frailty index based on routine laboratory tests and risk of cerebral small vessel disease in elderly patients: a hospital-based observational study[J]. Aging Cli Exp Res,2022,34(11):2683-2692.
[31] Del Brutto O H, Mera R M, Recalde B Y, et al. Mediation of age in the association between frailty and large artery atherosclerosis burden - A population study in community-dwelling older adults[J]. J Stroke Cerebrovasc Dis,2020,29(7):104-112.
[32] KANAI M, NOGUCHI M, KUBO H, et al.Pre-Stroke Frailty and Stroke Severity in Elderly Patients with Acute Stroke[J]. J Stroke Cerebrovasc Dis,2020,29(12):105-111
[33] NEWMAN A B, GOTTDIENER J S, MCBURNIE M A, et al.Associations of subclinical cardiovascular disease with frailty[J]. J Gerontol A Biol Sci Med Sci,2001,56(3):158-166.
[34] DAMLUJI A A, CHUNG S E, XUE Q L, et al.Frailty and cardiovascular outcomes in the National Health and Aging Trends Study[J]. Eur Heart J,2021,42(37):3856-3865.
[35] WALSTON J, MCBURNIE M A, NEWMAN A, et al.Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study[J]. Arch Intern Med,2002,162(20):2333-2341.
[36] RIDKER P M, LIBBY P, MACFADYEN J G, et al.Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)[J]. Eur Heart J,2018,39(38):3499-3507.
[37] KOCHAR B, ORKABY A R, ANANTHAKRISHNAN A N, et al.Frailty in inflammatory bowel diseases: an emerging concept[J]. Therap Adv Gastroenterol,2021,14:175-184.
[38] BIGEH A, SANCHEZ A, MAESTAS C, et al.Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?[J]. Trends Cardiovasc Med,2020,30(8):463-469.
[39] KAMPERIDIS N, KAMPERIDIS V, ZEGKOS T, et al.Atherosclerosis and Inflammatory Bowel Disease-Shared Pathogenesis and Implications for Treatment[J]. Angiology,2021,72(4):303-314.